levoketoconazole
Selected indexed studies
- Levoketoconazole. (Am J Health Syst Pharm, 2022) [PMID:35266967]
- Levoketoconazole. (Hosp Pharm, 2022) [PMID:36081533]
- Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. (Expert Rev Endocrinol Metab, 2021) [PMID:34380370]
_Worker-drafted node — pending editorial review._
Connections
levoketoconazole is a side effect of
Sources
- Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment. (2021) pubmed
- Levoketoconazole. (2022) pubmed
- Levoketoconazole. (2022) pubmed
- Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. (2021) pubmed
- Efficacy and Safety of Levoketoconazole in Managing Cushing's Syndrome: A Systematic Review. (2024) pubmed
- Ketoconazole. (2006) pubmed
- Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). (2022) pubmed
- New Trends in Treating Cushing's Disease. (2024) pubmed
- Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. (2021) pubmed
- Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. (2022) pubmed